MX2021003357A - Procedimiento para la preparacion de una forma de dosificacion oral de multiples unidades de liberacion modificada de succinato de doxilamina y clorhidrato de piridoxina. - Google Patents
Procedimiento para la preparacion de una forma de dosificacion oral de multiples unidades de liberacion modificada de succinato de doxilamina y clorhidrato de piridoxina.Info
- Publication number
- MX2021003357A MX2021003357A MX2021003357A MX2021003357A MX2021003357A MX 2021003357 A MX2021003357 A MX 2021003357A MX 2021003357 A MX2021003357 A MX 2021003357A MX 2021003357 A MX2021003357 A MX 2021003357A MX 2021003357 A MX2021003357 A MX 2021003357A
- Authority
- MX
- Mexico
- Prior art keywords
- modified release
- preparation
- dosage form
- oral dosage
- multiple unit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada que comprende una pluralidad de pellets de liberación modificada de doxilamina o una sal de la misma y una pluralidad de pellets de liberación modificada de piridoxina o una sal de la misma, en el que el procedimiento comprende recubrir los pellets de doxilamina que tienen la capa de recubrimiento activa interna y la capa de recubrimiento entérico intermedia y los pellets de piridoxina que tienen la capa de recubrimiento activa interna, en el que la etapa de recubrimiento comprende la pulverización simultánea de una mezcla que comprende los agentes de recubrimiento de liberación entérica y modificada y la adición de agentes formadores de poros en forma de polvo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18382687.4A EP3628311B1 (en) | 2018-09-27 | 2018-09-27 | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride |
PCT/EP2019/076140 WO2020064985A1 (en) | 2018-09-27 | 2019-09-27 | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003357A true MX2021003357A (es) | 2021-08-11 |
Family
ID=63722327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003357A MX2021003357A (es) | 2018-09-27 | 2019-09-27 | Procedimiento para la preparacion de una forma de dosificacion oral de multiples unidades de liberacion modificada de succinato de doxilamina y clorhidrato de piridoxina. |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP3628311B1 (es) |
JP (1) | JP7444862B2 (es) |
KR (1) | KR20210066864A (es) |
CN (1) | CN112839638B (es) |
AR (1) | AR116480A1 (es) |
AU (1) | AU2019348630B2 (es) |
BR (1) | BR112021005192A8 (es) |
CL (1) | CL2021000687A1 (es) |
CO (1) | CO2021005412A2 (es) |
CR (1) | CR20210208A (es) |
CY (1) | CY1123785T1 (es) |
DK (1) | DK3628311T3 (es) |
DO (1) | DOP2021000052A (es) |
EA (1) | EA202190700A1 (es) |
EC (1) | ECSP21029863A (es) |
ES (1) | ES2847648T3 (es) |
HR (1) | HRP20210181T1 (es) |
HU (1) | HUE053082T2 (es) |
MX (1) | MX2021003357A (es) |
MY (1) | MY197676A (es) |
NI (1) | NI202100021A (es) |
PE (1) | PE20211462A1 (es) |
PH (1) | PH12021550640A1 (es) |
PL (1) | PL3628311T3 (es) |
PT (1) | PT3628311T (es) |
RS (1) | RS61368B1 (es) |
SA (1) | SA521421557B1 (es) |
SI (1) | SI3628311T1 (es) |
UA (1) | UA127768C2 (es) |
WO (1) | WO2020064985A1 (es) |
ZA (1) | ZA202101279B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
KR20090005237A (ko) * | 2006-05-22 | 2009-01-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 둘록세틴 염산염 지연 방출형 제제 |
ES2376095B1 (es) * | 2008-10-02 | 2013-01-24 | Laboratorios Del Dr. Esteve, S.A. | Pellets entéricos de duloxetina. |
CA2761212A1 (en) * | 2011-12-07 | 2013-06-07 | Pharmascience Inc. | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing |
WO2013123569A1 (en) | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
HUE052301T2 (hu) * | 2012-02-22 | 2021-04-28 | Duchesnay Inc | Doxil-amin és piridoxin és/vagy metabolitjainak vagy sóinak készítmény |
CN103142552A (zh) * | 2013-02-22 | 2013-06-12 | 广州科的信医药技术有限公司 | 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法 |
CN103690506B (zh) * | 2013-11-08 | 2015-05-13 | 舒泰神(北京)生物制药股份有限公司 | 一种曲司氯铵缓释组合物及其制备方法 |
PL3185856T3 (pl) | 2014-08-29 | 2018-09-28 | Duchesnay Inc. | Wielomodalne formulacje uwalniania doksylaminy i pirydoksyny i/lub ich metabolitów lub soli |
US10111838B2 (en) * | 2014-11-26 | 2018-10-30 | Evonik Roehm Gmbh | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
CN106606502B (zh) * | 2015-10-27 | 2019-12-31 | 四川海思科制药有限公司 | 一种琥珀酸多西拉敏盐酸吡哆醇肠溶片药物组合物及其制备方法 |
-
2018
- 2018-09-27 ES ES18382687T patent/ES2847648T3/es active Active
- 2018-09-27 DK DK18382687.4T patent/DK3628311T3/da active
- 2018-09-27 RS RS20210089A patent/RS61368B1/sr unknown
- 2018-09-27 EP EP18382687.4A patent/EP3628311B1/en active Active
- 2018-09-27 PL PL18382687T patent/PL3628311T3/pl unknown
- 2018-09-27 SI SI201830208T patent/SI3628311T1/sl unknown
- 2018-09-27 PT PT183826874T patent/PT3628311T/pt unknown
- 2018-09-27 HU HUE18382687A patent/HUE053082T2/hu unknown
-
2019
- 2019-09-23 AR ARP190102692A patent/AR116480A1/es unknown
- 2019-09-27 PE PE2021000345A patent/PE20211462A1/es unknown
- 2019-09-27 CN CN201980063235.6A patent/CN112839638B/zh active Active
- 2019-09-27 UA UAA202101817A patent/UA127768C2/uk unknown
- 2019-09-27 AU AU2019348630A patent/AU2019348630B2/en active Active
- 2019-09-27 JP JP2021516918A patent/JP7444862B2/ja active Active
- 2019-09-27 WO PCT/EP2019/076140 patent/WO2020064985A1/en active Application Filing
- 2019-09-27 EA EA202190700A patent/EA202190700A1/ru unknown
- 2019-09-27 CR CR20210208A patent/CR20210208A/es unknown
- 2019-09-27 MX MX2021003357A patent/MX2021003357A/es unknown
- 2019-09-27 KR KR1020217012326A patent/KR20210066864A/ko active Search and Examination
- 2019-09-27 BR BR112021005192A patent/BR112021005192A8/pt unknown
- 2019-09-27 MY MYPI2021001522A patent/MY197676A/en unknown
-
2021
- 2021-01-27 CY CY20211100065T patent/CY1123785T1/el unknown
- 2021-02-02 HR HRP20210181TT patent/HRP20210181T1/hr unknown
- 2021-02-25 ZA ZA2021/01279A patent/ZA202101279B/en unknown
- 2021-03-19 CL CL2021000687A patent/CL2021000687A1/es unknown
- 2021-03-19 PH PH12021550640A patent/PH12021550640A1/en unknown
- 2021-03-23 NI NI202100021A patent/NI202100021A/es unknown
- 2021-03-24 SA SA521421557A patent/SA521421557B1/ar unknown
- 2021-03-26 DO DO2021000052A patent/DOP2021000052A/es unknown
- 2021-04-26 EC ECSENADI202129863A patent/ECSP21029863A/es unknown
- 2021-04-26 CO CONC2021/0005412A patent/CO2021005412A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017010858A (es) | Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6. | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
MX2022006422A (es) | Derivado de cicloalquilurea. | |
MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
PH12021550640A1 (en) | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride | |
MY194941A (en) | C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same | |
GEP20186909B (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
MX2021003033A (es) | Formulaciones de compuestos de cicloserina y aplicaciones de estas. | |
MX2018010065A (es) | Forma de dosificacion oral que comprende rifaximina en forma beta. | |
SA517380942B1 (ar) | صيغة إطلاق متعددة النماذج للدوكسيلامين والبيريدوكسين و/أو نواتج أيض أو أملاح منها | |
MX2018009749A (es) | Formulaciones de esferas farmacéuticas que comprenden dimetilfumarato. | |
TW201613584A (en) | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | |
PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
MX2018002449A (es) | Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas. | |
PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
WO2020046243A3 (en) | Extended release osmotic tablet dosage form comprising metformin and sitagliptin |